Immunotherapy to cure chronic hepatitis B virus infections
Unsuccessful clearance of hepatitis B virus in chronic patients leads to serious liver problems including liver cancer. Boosting and/or inducing T cell responses against multiple conserved viral antigens with Synthetic Long Peptide immunotherapy may offer a cure. Together Erasmus MC and ISA pharmaceuticals designed and validated the active ingredients.
The aim of this project was to contribute to the development of an immunotherapy for chronic hepatitis B to cure the disease and reduce patient risk to develop end-stage liver disease
More detailed information
Role Erasmus MC: